- Open Access
Growth hormone exacerbates diabetic renal damage in male but not female rats
© Whitney et al.; licensee BioMed Central Ltd. 2013
- Received: 21 March 2013
- Accepted: 18 June 2013
- Published: 27 June 2013
Human and animal studies support the idea that there are sex differences in the development of diabetic renal disease. Our lab and others have determined that in addition to Ang II (through the AT1R), growth hormone (GH) contributes to renal damage in models of renal failure; however, the impact of sex and GH on the mechanisms initiating diabetic renal disease is not known. This study examined the effect of sex and GH on parameters of renal damage in early, uncontrolled streptozotocin (STZ)-induced diabetes.
Adult male and female Sprague–Dawley rats were injected with vehicle (control), STZ, or STZ + GH and euthanized after 8 weeks.
Mild but significant glomerulosclerosis (GS) and tubulointerstitial fibrosis (TIF) was observed in both kidneys from male and female diabetic rats, with GH significantly increasing GS and TIF by 30% and 25% in male rats, but not in female rats. STZ increased TGF-β expression in both kidneys from male and female rats; however, while GH had no further effect on TGF-β protein in diabetic females, GH increased TGF-β protein in the male rat’s kidneys by an additional 30%. This sex-specific increase in renal injury following GH treatment was marked by increased MCP-1 and CD-68+ cell density. STZ also reduced renal MMP-2 and MMP-9 protein expression in both kidneys from male and female rats, but additional decreases were only observed in GH-treated diabetic male rats. The sex differences were independent of AT1R activity.
These studies indicate that GH affects renal injury in diabetes in a sex-specific manner and is associated with an increase in pro-inflammatory mediators.
- Sex Differences
- Renal Injury
Growth hormone (GH) has been shown to exacerbate progression of kidney damage in a number of experimental models of renal disease [1–4], including diabetes . Indeed, the kidney appears to be very sensitive to GH, as seen in male transgenic mice overexpressing GH that present with glomerular hypertrophy, increased glomerular cell turnover, and increased extracellular matrix accumulation leading to diffuse glomerulosclerosis [6, 7]. It has also been reported that diabetic patients present with dysregulation of GH, which ultimately results in overall GH hypersecretion . Diabetic mice treated with a specific GH receptor antagonist showed none of the diabetes-associated renal hypertrophy or glomerular enlargement and had lower urinary albumin excretion than untreated diabetic mice [5, 9]. These results were confirmed in GH receptor antagonist transgenic mice that were protected against diabetes-induced renal changes . Collectively, these findings strongly suggest that GH plays a role in the development of diabetic renal disease; however, the mechanism whereby GH acts on the kidney is not completely understood. While GH is known to stimulate liver and tissue insulin-like growth factor (IGF-1), this IGF-I associated mechanism does not appear to play a role in diabetic renal damage .
In the streptozotocin (STZ)-induced diabetic rat, a common diabetic rat model, normal GH secretion is dysregulated . Indeed, by 6 h post-STZ, pulsatile GH secretion is dramatically reduced in male rats and is abolished by 12 h . Suppression of plasma GH by STZ is also observed in female rats (unpublished data from this laboratory). This decrease seen in GH levels is opposite of what is seen in patients with type 1 diabetes, where GH levels are dysregulated, and usually elevated compared to nondiabetic control patients [8, 12]. We hypothesize that the loss of GH in the STZ model impacts the development of diabetic kidney disease and that using an STZ model with GH supplementation will more accurately reflect the human condition.
Another important aspect of human diabetes is the increasing evidence of sex differences in the development and/or severity of diabetic renal disease [13–16], and although sex hormones appear to be key factors [17, 18], the exact reasons for the differences are still not clear. In addition, both sex and diabetes are key factors contributing to cardiovascular diseases [19–22]. Our lab has previously reported the link between GH and the development of renal disease following unilateral nephrectomy [4, 17]. More importantly, we have identified sex differences in the effects of GH on remnant kidney growth and pathology and determined that GH is crucial in compensatory renal growth in male animals, but not in female animals [17, 23]. While many renal diseases have been shown to progress at different rates between the sexes, these findings indicate that there are differential pathologic pathways governed by gonadal steroids, with testosterone promoting a GH-dependent, hypertrophic renal growth, and 17β-estradiol promoting IGF-1-associated hyperplastic renal growth [16, 17, 23]. On this basis, we hypothesize that there also may be sex differences in GH-mediated diabetic renal damage.
Taken together, there is a strong rationale for sex differences in the development of diabetic renal disease, and GH may be a contributing factor to these differences. Since sex hormones can affect renal hemodynamics, mesangial cell proliferation, extracellular matrix metabolism, as well as synthesis and release of vasoactive agents , their role in diabetes could help define sex-specific therapeutic interventions. Thus, the objective of this study was to determine the effects of sex and GH on mediators of renal damage and subsequent renal disease in the initial stage of uncontrolled diabetes.
Male and female Sprague–Dawley rats (Harlan, Madison, WI, USA) (12–14 weeks of age), were randomly divided into three treatment groups for each sex: control (n = 10), streptozotocin (n = 8), and STZ + GH (n = 9). After fasting animals overnight, diabetes was induced by an intraperitoneal injection of STZ (55 mg/kg in 100 μl 0.1 M citrate) in the STZ and STZ + GH groups, whereas control animals were injected with vehicle (100 μl 0.1 M citrate). Because there are sex differences in GH secretory patterns (regular high pulses in males ) and higher baseline, erratic, and low pulses in females , we performed a pilot study using twice daily GH injections (which we have used successfully in many studies) vs continual GH release via an osmotic minipump, and the damage to both male and female kidneys were similar between each method (data not shown). We decided to use the GH injections primarily because of our past success with this method. The GH-supplemented diabetic rats (STZ + GH) were injected subcutaneously with GH twice daily over the 8-week duration of the experiment (2.5 μg in 100 μl saline between 9–11 a.m. and 3–5 p.m.), whereas the non-GH-treated rats were injected twice daily with vehicle (100 μl saline). This dose has been shown to increase plasma GH to 80–100 mmol/l within 30 min, which is similar to levels observed in male rats . All animals were fed a phytoestrogen-free diet (Harlan) and given tap water ad libitum. Twenty-four-hour urine was collected from rats placed in metabolic cages after 0, 4, and 8 wks of treatment. Diabetic animals were not treated with insulin in order to mimic the changes present in early uncontrolled diabetes. Plasma glucose was determined using a One-Touch Ultra glucometer (LifeScan, Milpitas, CA, USA) from blood collected via tail puncture at day 0 and thereafter on a weekly basis during the course of the entire experiment. Animals were sacrificed by decapitation. The left kidney was weighed, removed, and snap-frozen in liquid nitrogen for analysis of TGF-β, MMP-2, MMP-9 protein expression by Western blotting and AT1R activity by radioligand binding. The right kidney was fixed in 4% paraformaldehyde for assessment of glomerulosclerosis and tubulointerstitial fibrosis as well as tissue expression of monocyte chemoattractant protein-1 (MCP-1)- and CD68-positive cells by immunohistochemistry. Urine albumin concentration was determined by ELISA (Exocell, Philadelphia, PA, USA) and multiplied by urine volume to calculate urine albumin excretion. All procedures were approved by the Georgetown University Animal Care and Use Committee.
Renal cortex was prepared for Western blotting by rapidly dissecting frozen kidney tissue on ice, followed by homogenization using the Bio-Rad’s Criterion system (Hercules, CA, USA), as previously described . Briefly, total protein (30 mg) was loaded in each lane followed by electrophoresis on 10% polyacrylamide gels. The gels were incubated with one of the following primary antibodies: TGF-β (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), MMP-2 (1:500, Oncogene Science, Cambridge, MA, USA), and MMP-9 (1:500, Oncogene Sciences). Specific bands were detected by chemiluminescent peroxidase (Amersham, Buckinghamshire, UK) and recorded on X-ray film. Relative density of bands was determined by normalizing each band to lane total protein density determined by a Coomassie blue stain. Corresponding samples of male and female homogenates were compared side by side on the same gel.
Because we have previously reported sex-dependent increases in AT1R binding by GH in another model of renal disease  and identified sex-hormone-dependent effects on AT1R binding , we examined whether renal AT1R binding was altered by GH in diabetic male and female animals. Specific AT1R binding was determined in isolated glomeruli (5 μg/tube) using 125I-[Sar1, Ile8]Ang II as the radioligand, as previously described . Specific binding was defined as the total binding in the presence of radioligand minus the amount of binding in the presence of radioligand and 500 μM cold [Sar1, Ala8]Ang II.
Periodic acid Schiff-stained, paraffin-embedded kidney sections (3 μm) were examined using a Nikon Eclipse E600 (Tokyo, Japan) light microscope to assess the glomerulosclerotic index (GSI), as previously described .
Tubulointerstitial fibrosis index
Masson’s trichrome-stained 3-μm paraffin-embedded kidney sections were examined using a Nikon Eclipse E600 light microscope to assess the TIFI, as previously described .
Paraffin sections at 3 μm were incubated in 10% normal goat serum for 30 min at room temperature, followed by incubation overnight at 4°C with one of the following primary antibodies: MCP-1 (1:100, Santa Cruz), CD68 (1:100, Oncogene Sciences), and TGF-β (1:400, Santa Cruz). Negative controls were incubated in 10% normal goat serum only. Positive immunoreactivity was detected using the Envision Plus peroxidase method (Dako, Carpentaria, CA, USA), followed by counterstaining the slides with Mayer’s hematoxylin. The images were taken at × 400. The samples were quantitated by analyzing 25 randomly chosen visual fields per animal. The positive cell number was determined by counting the number of cortical positive cells (brown staining) in 25 different fields per animal from each group and expressed as the average percentage of brown staining in the field of view. Images were quantified using Image145 J software (National Institutes of Health http://rsbweb.nih.gov/ij/).
Statistical analysis between groups was performed using one-way ANOVA, with Student-Neuman-Keul’s post hoc tests. Significance was designated at P < 0.05.
Effects of GH and sex on blood glucose and albuminuria
Blood glucose levels were elevated more than fourfold in all diabetic animals starting by week 1 (control, 100 ± 11 mg/dl; STZ, >400 mg/dl; STZ + GH, >400 mg/dl; P < 0.01, control vs STZ or STZ + GH) and remained elevated throughout the experimental period (data not shown). There was no additional effect of GH on blood glucose nor were there sex differences seen in blood glucose within treatment groups, with the limitation that all STZ groups were shown with blood glucose above 400 mg/dl.
Effect of treatment on body weight, kidney weight, heart weight, and albuminuria of rats
Initial BW (g)
Final BW (g)
244.5 ± 5.5
284.0 ± 9.0
1.52 ± 0.04
0.99 ± 0.11
2.9 ± 1.2
225.3 ± 1.8
201.0 ± 4.4*
2.20 ± 0.02*
0.94 ± 0.04
11.3 ± 2.7*
STZ + GH
227.4 ± 2.3
227.4 ± 18.7
2.36 ± 0.11*
0.95 ± 0.07
8.6 ± 1.8*
369.7 ± 2.7
461.0 ± 14.0
2.68 ± 0.10
1.42 ± 0.02
3.1 ± 0.4
352.8 ± 8.1
251.8 ± 22.0**
2.75 ± 0.21
1.00 ± 0.08**
10.4 ± 0.8**
STZ + GH
353.0 ± 8.7
249.0 ± 25.6**
2.85 ± 0.19
1.13 ± 0.10**
16.1 ± 1.7**,***
Kidney weight (KW) was not affected by STZ treatment or GH supplementation in the male rats (Table 1). In contrast, KW increased by 1.4-fold in the females after STZ treatment, while GH supplementation had no additional effect.
STZ treatment reduced heart weight (HW) in the male rats and GH supplementation had no additional effect (Table 1). In comparison, STZ had no effect on HW in the females either in the presence or absence of GH supplementation.
Urine albumin excretion was elevated in both male (3.5-fold) and female (3.9-fold) STZ-treated rats compared with their same-sex controls (Table 1). GH supplementation increased the amount of albumin excreted in the diabetic male to 5.2-fold but had no additional effect on albuminuria in the diabetic female.
Effects of GH and sex on glomerular and tubular damage
Effect of sex and GH on renal markers of inflammation (MCP-1 and CD68)
Effect of sex and GH on renal TGF-β and MMP-2 and MMP-9
Effect of GH on glomerular AT1R binding
Renal glomerular AT1R binding was tested. As previously reported , AT1R binding was significantly lower in the glomeruli from nondiabetic female animals compared with male animals (4,234 ± 178 cpm vs. 6,742 ± 210 cpm, P < 0.05). AT1R binding was not significantly changed in STZ-only-treated male and female glomeruli (3,934 ± 1,084 cpm vs. 5,037 ± 596 cpm). However, in both male and female STZ + GH-treated rats, AT1R binding significantly increased as compared to control and STZ-only-treated rats (8,462 ± 923 cpm vs. 9,562 ± 1,472 cpm, P < 0.05) (graph not shown).
While previous studies have highlighted the issues of sex differences and GH effects in diabetic renal disease separately, the present work shows sex-related differences in response to GH in diabetic renal disease. The presence of GH appears to be necessary for the development of significant renal damage, but there are sex differences in the pattern of effects of GH on the diabetic kidney. Our findings have determined that GH has a greater overall effect in the male animals in proteins associated with renal damage (increased TGF-β, MCP-1 and CD-68, and lowered MMPs) and markers of pathology (increased GSI, TIFI, and albuminuria). GH was given at a fixed amount that has been shown to achieve levels similar to that observed in adult male rats (unpublished data). Because it was not adjusted for BW, the female rats received a greater proportional dosage, yet it did not exacerbate the renal damage, providing further evidence that the effect on the kidneys is specific to male animals. These findings extend previous reports and provide intriguing areas for future study. Furthermore, the fact that human diabetes is associated with overall elevated plasma GH [8, 12] increases the relevance of the present work.
The STZ-treated rat is an excellent model for studying the role of GH in diabetes, since STZ treatment results in the suppression of pulsatile GH release and low plasma GH levels : this low GH model can then be compared to STZ + GH replacement to identify GH-related changes in diabetes. This has allowed us to identify the differential patterns of response to GH in male and female diabetic animals. Consistent with previous reports, in both male and female animals, STZ treatment increases cortical TGF-β expression and decreases cortical MMP-2 and MMP-9 [27, 28]. While GH increases AT1R binding in the diabetic female kidney, it does not increase other proteins associated with renal inflammation and damage (e.g., TGF-β, MCP-1, CD68, and MMPs) or exacerbate renal pathology. Our findings indicate that there are both AT1R-dependent and AT1R-independent actions of GH in the female diabetic kidney. Males showed a similar response to STZ, but all of the protein changes were amplified with GH and directly associated with exacerbation of renal morphologic damage. This differential GH action may be mediated by interactions involving testosterone and GH. Testosterone treatment alone has been shown to increase renal TGF-β mRNA and protein levels in vivo, which was followed by an increase in glomerulosclerosis as well as an increase in lymphocyte and macrophage infiltration . These protein changes and resulting pathology were reversed with flutamide treatment (a nonsteroidal antiandrogen). In the present study, we did not see sex differences with STZ treatment alone, suggesting that both testosterone and GH are needed to uncover these sex differences.
Evidence suggests that a pro-inflammatory response contributes to the development of diabetic renal disease [30–32]. The infiltration of immune cells seen in many glomerular diseases could cause structural damage through the release of proteolytic enzymes and oxygen-free radicals, glomerular remodeling by the release of growth factors, or glomerular functional alternations through the release of pro-inflammatory cytokines [33, 34]. Previous studies have shown that elevations in cytokines, such as TGF-β and IL-6, presage the development of the disease [30, 35, 36]. This pattern has also been found in the current study, and importantly, we found sex differences associated with this pro-inflammatory response. In strong support of differential GH-related mechanisms is the finding that GH has a dramatic effect on renal TGF-β in diabetic male animals, but not in female animals. This increase is directly correlated with exacerbated renal damage (increased GSI, TIFI, and albuminuria) in the male kidney. A previous study in STZ-diabetic mice reported that MCP-1 promotes renal damage . In our study, elevations in MCP-1 were also associated with renal damage, but importantly, the stimulation of MCP-1 by GH is also affected by the sex of the animal. Interestingly, while MCP-1 is elevated to the same extent in the STZ-only-treated male and female rats, CD68+ cells (representing activated macrophages) are only elevated in the STZ + GH-treated male rat kidneys. This suggests that the 2-month period of untreated diabetes is sufficient to produce renal damage but that the exacerbation of the damage in the male may be due to the activation of the macrophages, whereas the pro-inflammatory damage observed in the STZ-only-treated animals may be independent of this effect.
The stimulation of TGF-β by GH has been reported by others ; however, sex differences are a novel finding and suggest that another mechanism is modulating the effect of GH on TGF-β in the female. Potentially, GH might use testosterone as a mediator for an increase in TGF-β; this might provide a layer of protection in the female against some of the early damage observed in the diabetic male. Indeed, a relationship has been suggested between E2 and TGF-β since E2 supplementation in (nondiabetic) TGF-β transgenic mice significantly reduces GS and TIF . In our diabetic females, the presence of E2, albeit at a reduced level , may provide this protection against the actions of GH on TGF-β. Future studies in ovariectomized diabetic females with or without GH could illuminate this issue.
The concept that GH may provide another target for therapy in diabetes has been suggested  and is supported by many animal studies over the past 15 years [9, 10, 37]. Our data support the idea of this GH pharmacologic therapy for the treatment of diabetic kidney disease but suggest that it is especially relevant in males. Previous reports of GH antagonist treatment from the onset of diabetes found a normalization of diabetes-induced renal effects, including reduced renal hypertrophy, glomerular hypertrophy, and urine albumin content; however, these studies were only in male experimental animals . It has also been shown that late intervention with a GH antagonist resulted in regression of some of diabetes-associated renal changes . The present findings suggest that this potential therapy may be useful only in men.
In conclusion, sex differences exist in the mechanisms governing early, uncontrolled diabetes in the presence of GH. The male response to GH indicates significantly more pathology and damage than in females, suggesting evidence for differential sex-related pharmacologic treatments.
This work was supported by grants from NIH R01 DK064916 and the National Kidney Foundation of the Nation’s Capital Area for Susan E Mulroney, NIH R01 HL57502 for Kathryn Sandberg, and Juvenile Diabetes Association Award and NIH DK075832 for Christine Maric Bilkan.
- Bellush LL, Doublier S, Holland AN, Striker LJ, Striker GE, Kopchick JJ: Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 2000,141(1):163–168. 10.1210/en.141.1.163PubMedGoogle Scholar
- Doi SQ, Rasaiah S, Tack I, Mysore J, Kopchick JJ, Moore J, Hirszel P, Striker LJ, Striker GE: Low-protein diet suppresses serum insulin-like growth factor-1 and decelerates the progression of growth hormone-induced glomerulosclerosis. Am. J. Nephrol. 2001,21(4):331–339. 10.1159/000046270PubMedView ArticleGoogle Scholar
- Flyvbjerg A, Bennett WF, Rasch R, van Neck JW, Groffen CA, Kopchick JJ, Scarlett JA: Compensatory renal growth in uninephrectomized adult mice is growth hormone dependent. Kidney Int. 1999,56(6):2048–2054. 10.1046/j.1523-1755.1999.00776.xPubMedView ArticleGoogle Scholar
- Mok KY, Sandberg K, Sweeny JM, Zheng W, Lee S, Mulroney SE: Growth hormone regulation of glomerular AT1 angiotensin receptors in adult uninephrectomized male rats. Am J Physiol Renal Physiol 2003,285(6):F1085-F1091.PubMedView ArticleGoogle Scholar
- Flyvbjerb A: The role of growth hormone in the pathogenesis of kidney disease. Pediatric Endocrinology Review 2004,1(Suppl 3):535–539.Google Scholar
- Doi T, Striker LJ, Quaife C, Conti FG, Palmiter R, Behringer R, Brinster R, Striker GE: Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin-like growth factor-1. Am J Pathol 1988, 131: 398–403.PubMed CentralPubMedGoogle Scholar
- Pesce CM, Striker LJ, Peten E, Elliot S, Striker GE: Glomerulosclerosis at both early and late stages is associated with increased cell turnover in mice transgenic for growth hormone. Lab Invest 1991, 65: 601–605.PubMedGoogle Scholar
- Bereket A, Lang CH, Wilson TA: Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999,31(2–3):172–181.PubMedView ArticleGoogle Scholar
- Flyvbjerb A: Potential use of growth hormone receptor antagonist in the treatment of diabetic kidney disease. GH IGF Res 2001, 11: S115-S119.Google Scholar
- Chen N-Y, Chen WY, Bellush L, Yang CW, Striker LJ, Striker GE, Kopchick JJ: Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995, 136: 660–667. 10.1210/en.136.2.660PubMedGoogle Scholar
- Phillip M, Segeve Y, Zung A, Kowarski AA, Werner H, Roberts CT Jr, LeRoith D, Ladas JG, Mulroney SE: The accumulation of IGF-I in kidneys of streptozotocin-diabetic adult rats is not associated with elevated plasma GH and IGF-I levels. Endocrine 1995, 3: 689–693. 10.1007/BF02746346PubMedView ArticleGoogle Scholar
- Hansen AP, Johansen K: Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970,6(1):27–33. 10.1007/BF00425888PubMedView ArticleGoogle Scholar
- Costacou T, Fried L, Ellis D, Orchard TJ: Sex differences in the development of kidney disease in individuals with type 1 diabetes mellitus: a contemporary analysis. Am J Kidney Dis 2011,58(4):565–573. 10.1053/j.ajkd.2011.05.025PubMed CentralPubMedView ArticleGoogle Scholar
- Maric C: Sex, diabetes and the kidney. Am J Physiol Renal Physiol 2009, 296: F680-F688. 10.1152/ajprenal.90505.2008PubMed CentralPubMedView ArticleGoogle Scholar
- Silbiger SR, Neugarten J: The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995, 25: 515–533. 10.1016/0272-6386(95)90119-1PubMedView ArticleGoogle Scholar
- Silbiger MD, Neugarten J: Gender and human chronic renal disease. Gend Med 2008, 5: S3-S10.PubMedView ArticleGoogle Scholar
- Mulroney SE, Woda C, Johnson M, Pesce C: Gender differences in renal growth and function after uninephrectomy in adult rats. Kidney Int. 1999,56(3):944–953. 10.1046/j.1523-1755.1999.00647.xPubMedView ArticleGoogle Scholar
- Xu Q, Wells CC, Garman JH, Asico L, Escano CS, Maric C: Imbalance in sex hormone levels exacerbates diabetic renal disease. Hypertension 2008,51(4):1218–1224. 10.1161/HYPERTENSIONAHA.107.100594PubMed CentralPubMedView ArticleGoogle Scholar
- Heer T, Schiele R, Schneider S, Gitt AK, Wienbergen H, Gottwik M, Gieseler U, Voigtländer T, Hauptmann KE, Wagner S, Senges J: Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol 2002,89(5):511–517. 10.1016/S0002-9149(01)02289-5PubMedView ArticleGoogle Scholar
- Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979,2(2):120–126. 10.2337/diacare.2.2.120PubMedView ArticleGoogle Scholar
- Lee WL, Cheung AM, Cape D, Zinman B: Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000,23(7):962–928. 10.2337/diacare.23.7.962PubMedView ArticleGoogle Scholar
- Reckelhoff J: Gender difference in the regulation of blood pressure. Hypertension 2001,37(5):1199–1208. 10.1161/01.HYP.37.5.1199PubMedView ArticleGoogle Scholar
- Mulroney SE, Pesce C: Early hyperplastic renal growth after uninephrectomy in adult female rats. Endocrinology 2000,141(3):932–937. 10.1210/en.141.3.932PubMedGoogle Scholar
- Yanes LL, Romero DG, Iles JW, Iliescu R, Gomez-Sanchez C, Reckelhoff JF: Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2006,291(2):R383-R390. 10.1152/ajpregu.00510.2005PubMedView ArticleGoogle Scholar
- Rogers JL, Mitchell AR, Maric C, Sandberg K, Myers A, Mulroney SE: Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol 2007,292(2):R794-R799.PubMedView ArticleGoogle Scholar
- Mankhey RW, Bhatti F, Maric C: 17β-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol 2005,288(2):F399-F405.PubMedView ArticleGoogle Scholar
- Jacqueminet S, Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, Beaudeux JL: Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 2006,367(1–2):103–107.PubMedView ArticleGoogle Scholar
- Wang X, Yan L, Chen W, Xu L, Zheng X: The renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-beta expression in streptozocin-induced diabetic rats. J Int Med Res 2009,37(1):145–153. 10.1177/147323000903700117PubMedView ArticleGoogle Scholar
- Sun J, Devish K, Langer WJ, Carmines PK, Lane PH: Testosterone treatment promotes tubular damage in experimental diabetes in prepubertal rats. Am J Physiol Renal Physiol 2007,292(6):F1681-F1690. 10.1152/ajprenal.00482.2006PubMedView ArticleGoogle Scholar
- Choudhary N, Ahlawat RS: Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis 2008,2(2):72–79.PubMedGoogle Scholar
- Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006,69(1):73–80. 10.1038/sj.ki.5000014PubMedView ArticleGoogle Scholar
- Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004,65(1):116–128. 10.1111/j.1523-1755.2004.00367.xPubMedView ArticleGoogle Scholar
- Boyce NW, Tipping PG, Holdsworth SR: Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int 1989,35(3):778–782. 10.1038/ki.1989.52PubMedView ArticleGoogle Scholar
- Lovett DH, Ryan JL, Sterzel RB: Stimulation of rat mesangial cell proliferation by macrophage interleukin 1. J Immunol 1983,131(6):2830–2836.PubMedGoogle Scholar
- Seachrist D, Dunphy G, Daneshvar H, Caplea A, Milsted A, Ely D: Testosterone increases blood pressure and cardiovascular and renal pathology in spontaneously hypertensive rats. Blood Press 2000,9(4):227–238. 10.1080/080370500439128PubMedView ArticleGoogle Scholar
- Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996,45(4):522–530. 10.2337/diabetes.45.4.522PubMedView ArticleGoogle Scholar
- Thirone AC, Scarlett JA, Gasparetti AL, Araujo EP, Lima MH, Carvalho CR, Velloso LA, Saad MJ: Modulation of growth hormone signal transduction in kidneys of streptozotocin-induced diabetic animals: effect of a growth hormone receptor antagonist. Diabetes 2002,51(7):2270–2281. 10.2337/diabetes.51.7.2270PubMedView ArticleGoogle Scholar
- Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M: Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol 1999,10(11):2374–2381.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.